Dl-3-n-Butylphthalide Ameliorates Diabetic Nephropathy by Ameliorating Excessive Fibrosis and Podocyte Apoptosis.
diabetic nephropathy
dl-3-n-butylphthalide
endoplasmic reticulum stress
glomerular filtration barrier
podocytes
vascular endothelial growth factor
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
11
2020
accepted:
11
08
2021
entrez:
9
9
2021
pubmed:
10
9
2021
medline:
10
9
2021
Statut:
epublish
Résumé
Diabetic nephropathy (DN) is a common diabetes associated complication. Thus, it is important to understand the pathological mechanism of DN and find the appropriate therapeutic strategy for it. Dl-3-n-Butylphthalide (DL-NBP) has anti-inflammatory and antioxidant effects, and been widely used for the treatment of stroke and cardiovascular diseases. In this study, we selected three different doses (20, 60, and 120 mg⋅kg
Identifiants
pubmed: 34497508
doi: 10.3389/fphar.2021.628950
pii: 628950
pmc: PMC8419457
doi:
Types de publication
Journal Article
Langues
eng
Pagination
628950Informations de copyright
Copyright © 2021 Xu, Tang, He, Cai, Wang, Zhang, Wu, Qian, Zhang, Chai, Chen, Xu, Ji, Xiao and Wu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Mol Endocrinol. 2006 Apr;36(2):377-88
pubmed: 16595708
Exp Cell Res. 2014 Apr 1;322(2):290-301
pubmed: 24424244
Mol Cell Endocrinol. 2010 Jan 15;314(1):136-42
pubmed: 19765632
Diabet Med. 2011 May;28(5):549-59
pubmed: 21480966
Mol Med Rep. 2015 Feb;11(2):1448-54
pubmed: 25352064
Brain Res. 2010 Nov 4;1359:216-26
pubmed: 20800583
BMC Nephrol. 2015 Mar 31;16:44
pubmed: 25886386
Kidney Int. 2018 Jan;93(1):95-109
pubmed: 28750927
Sci Rep. 2017 Jul 31;7(1):6852
pubmed: 28761152
Metabolism. 2011 May;60(5):594-603
pubmed: 20817186
Chin Med J (Engl). 2019 Jun 20;132(12):1467-1477
pubmed: 31205106
Am J Physiol Renal Physiol. 2011 May;300(5):F1054-61
pubmed: 21345978
Oxid Med Cell Longev. 2018 Aug 16;2018:9125601
pubmed: 30186550
Front Pharmacol. 2020 Jan 24;10:1595
pubmed: 32038259
Nephron Exp Nephrol. 2009;112(1):e1-9
pubmed: 19342868
PLoS One. 2014 Mar 25;9(3):e92647
pubmed: 24667182
J Diabetes Res. 2013;2013:184539
pubmed: 24386643
Nat Rev Nephrol. 2010 Jun;6(6):319-30
pubmed: 20440277
Curr Drug Targets. 2011 Jan;12(1):107-14
pubmed: 20735351
Neurol Res. 2010 May;32(4):390-6
pubmed: 20483006
Oncotarget. 2017 May 16;8(20):32655-32667
pubmed: 28427241
Cardiovasc Res. 2010 Jul 15;87(2):262-71
pubmed: 20400620
Rev Recent Clin Trials. 2011 May;6(2):134-46
pubmed: 21241234
J Biol Chem. 2004 Jan 9;279(2):1458-67
pubmed: 14563845
Vasc Health Risk Manag. 2008;4(4):787-803
pubmed: 19065996
Kidney Int Suppl. 2003 Oct;(86):S64-70
pubmed: 12969130
Nat Rev Nephrol. 2011 Jun;7(6):327-40
pubmed: 21537349
Platelets. 2015;26(8):736-44
pubmed: 25734213
Sci Rep. 2017 Mar 23;7(1):323
pubmed: 28336924
J Diabetes Complications. 2003 Jan-Feb;17(1):1-6
pubmed: 12505748
Curr Med Chem. 2015;22(24):2858-70
pubmed: 26119175
Annu Rev Pathol. 2011;6:395-423
pubmed: 21261520
Diabetes. 2005 Jun;54(6):1626-34
pubmed: 15919782
Drug Des Devel Ther. 2018 Jul 13;12:2195-2211
pubmed: 30034224
Endocrinology. 2006 Dec;147(12):6011-8
pubmed: 16959849
Curr Diab Rep. 2008 Dec;8(6):470-6
pubmed: 18990304
Nat Rev Nephrol. 2014 Jul;10(7):369-78
pubmed: 24752014
World J Diabetes. 2014 Jun 15;5(3):393-8
pubmed: 24936261
Nat Med. 2013 Oct;19(10):1288-96
pubmed: 24056770
Ren Fail. 2001 May-Jul;23(3-4):483-93
pubmed: 11499563
Am J Physiol Renal Physiol. 2006 Apr;290(4):F927-36
pubmed: 16249273
J Clin Invest. 2014 Apr;124(4):1608-21
pubmed: 24590287
Science. 1999 Oct 8;286(5438):312-5
pubmed: 10514378
Cell Death Dis. 2019 Nov 7;10(11):848
pubmed: 31699972
Biomed Rep. 2019 Dec;11(6):235-240
pubmed: 31798868
Am J Physiol Renal Physiol. 2005 Jan;288(1):F117-24
pubmed: 15367390